↓ Skip to main content

The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status

Overview of attention for article published in Gastric Cancer, June 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
18 Mendeley
Title
The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
Published in
Gastric Cancer, June 2017
DOI 10.1007/s10120-017-0739-0
Pubmed ID
Authors

Ji Soo Park, Nare Lee, Seung Hoon Beom, Hyo Song Kim, Choong-kun Lee, Sun Young Rha, Hyun Cheol Chung, Mijin Yun, Arthur Cho, Minkyu Jung

Abstract

We aimed to find the clinical value of metastatic tumor burden evaluated with F18-FDG PET/CT in gastric cancer patients, considering the human epidermal growth factor receptor 2 (HER2) status. We retrospectively reviewed 124 patients with locally advanced or metastatic gastric cancer at Yonsei Cancer Center between January 2006 and December 2014 who had undergone baseline FDG PET/CT before first-line chemotherapy. We measured the maximum standardized uptake value from the primary tumor (SUVmax) and whole-body (WB) PET/CT parameters, including WB SUVmax, WB SUVmean, WB metabolic tumor volume (WB MTV), and WB total lesion glycolysis (WB TLG), in all metabolically active metastatic lesions (SUV threshold ≥2.5 or 40% isocontour for ≤2.5), and we determined their association with patient survival outcomes. SUVmax was higher in HER2-positive gastric cancers (median 12.1, range 3.4-34.6) compared to HER-2 negative (7.4, 1.6-39.1, P < 0.001). Among all patients, WB TLG > 600, which is indicative of a high metastatic tumor burden, showed worse progression-free survival (PFS) [hazard ratio (HR), 2.003; 95% CI, 1.300-3.086; P = 0.002] and overall survival (OS) (HR, 3.001; 95% CI, 1.950-4.618; P < 0.001) than did WB TLG ≤ 600. Among HER2-positive gastric cancer patients treated with trastuzumab, higher metabolic tumor burden predicted worse OS, but not PFS. HER2-positive gastric cancers had higher SUVmax compared to HER2-negative gastric cancers. In both HER2-negative patients and -positive patients receiving trastuzumab, FDG PET/CT volume-based parameters may have a role in further stratifying the prognosis of stage IV gastric cancer.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 22%
Student > Ph. D. Student 3 17%
Researcher 2 11%
Student > Doctoral Student 1 6%
Student > Bachelor 1 6%
Other 4 22%
Unknown 3 17%
Readers by discipline Count As %
Medicine and Dentistry 10 56%
Biochemistry, Genetics and Molecular Biology 1 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Sports and Recreations 1 6%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 4 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2018.
All research outputs
#20,429,992
of 22,982,639 outputs
Outputs from Gastric Cancer
#468
of 602 outputs
Outputs of similar age
#275,819
of 316,706 outputs
Outputs of similar age from Gastric Cancer
#7
of 11 outputs
Altmetric has tracked 22,982,639 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 602 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,706 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.